Simufilam is an investigational drug that represents an entirely new approach to treat Alzheimer’s disease.

Simufilam improves the function of multiple brain receptors and exerts powerful anti-neuroinflammatory effects. 

In 2018, we initiated a Phase II clinical program in patients with Alzheimer's disease using simufilam, backed by research grant awards from NIH.

SavaDx is our blood-based diagnostic to detect Alzheimer’s disease.

The goal of SavaDx is to make the detection of Alzheimer’s disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.